SC
ASND icon

Sapient Capital’s Ascendis Pharma A/S ASND Stock Holding History

Sapient Capital’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$21.8M Buy
95,721
+3,559
+4% +$902K 0.29% 44
2026
Q2 		$24.6M Buy
+92,162
New +$21.5M 0.32% 40

Other funds holding ASND

TFA
Toth Financial Advisory Leesburg, Virginia $1B AUM 19.18% 1-Year Est. Return
FWCM
Ferguson Wellman Capital Management Portland, Oregon $8.38B AUM 25.07% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
BONH
Bank of New Hampshire Laconia, New Hampshire $463M AUM 23.57% 1-Year Est. Return
RF
Roxbury Financial Mount Arlington, New Jersey $130M AUM 20.04% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
AAG
Armstrong Advisory Group Needham, Massachusetts $1.66B AUM 13.15% 1-Year Est. Return

Sapient Capital's ASND Position: Q3 2026 in Review

Sapient Capital increased its Ascendis Pharma A/S (ASND) stake by 3.9% in Q3 2026, buying an estimated $902K and bringing the position to 95,721 shares worth $21.8M. The position accounts for 0.29% of the portfolio, ranked #44.

Sapient Capital first reported a position in ASND in Q2 2026 and has held it in 2 quarters since. The position peaked at $24.6M in Q2 2026. 10 funds tracked by Wall St. Rank hold ASND as of Q3 2026.

  • Sapient Capital held 95,721 shares of Ascendis Pharma A/S worth $21.8M as of Q3 2026.
  • Sapient Capital bought 3,559 Ascendis Pharma A/S shares in Q3 2026, an estimated $902K.
  • Ascendis Pharma A/S made up 0.29% of Sapient Capital's portfolio in Q3 2026, its #44 holding.
  • Sapient Capital first reported a position in Ascendis Pharma A/S in Q2 2026 and has held it in 2 quarters since.
  • Sapient Capital's Ascendis Pharma A/S position peaked at $24.6M in Q2 2026.
  • 10 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q3 2026.

Based on Sapient Capital's 13F filing for Q3 2026, filed 8 Oct 2026.